Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

PBYI

Puma Biotechnology Inc

Feb 06 • 04:00PM ET

6.94

+0.15 2.21 %

Healthcare • Biotechnology • USA • NASD

Peers: INCY MRNA EXEL SRPT BPMC KYNB NKTR KPTI LGND AFMD

| Held by: AVUV VTI IWM IWN VXF BSVO VTWO DFAS FESM DFAT

Index	RUT	P/E	9.37	EPS (ttm)	0.74	Insider Own	24.09%	Shs Outstand	50.38M	Perf Week	7.10%
Market Cap	349.71M	Forward P/E	17.35	EPS next Y	0.40	Insider Trans	-0.61%	Shs Float	38.25M	Perf Month	13.96%
Enterprise Value	294.28M	PEG	-	EPS next Q	0.19	Inst Own	60.31%	Short Float	9.39%	Perf Quarter	40.34%
Income	36.98M	P/S	1.65	EPS this Y	-11.29%	Inst Trans	2.00%	Short Ratio	7.38	Perf Half Y	110.94%
Sales	212.00M	P/B	3.03	EPS next Y	-27.27%	ROA	17.46%	Short Interest	3.59M	Perf YTD	16.64%
Book/sh	2.29	P/C	3.62	EPS next 5Y	-5.09%	ROE	39.69%	52W High	7.28 -4.74%	Perf Year	136.86%
Cash/sh	1.91	P/FCF	8.16	EPS past 3/5Y	- -	ROIC	30.78%	52W Low	2.58 169.51%	Perf 3Y	59.54%
Dividend Est.	-	EV/EBITDA	6.59	Sales past 3/5Y	-3.08% -3.28%	Gross Margin	76.91%	Volatility	5.58% 4.79%	Perf 5Y	-42.79%
Dividend TTM	-	EV/Sales	1.39	EPS Y/Y TTM	56.02%	Oper. Margin	15.83%	ATR (14)	0.31	Perf 10Y	-83.37%
Dividend Ex-Date	-	Quick Ratio	1.62	Sales Y/Y TTM	-12.96%	Profit Margin	17.44%	RSI (14)	61.82	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.74	EPS Q/Q	-57.99%	SMA20	5.51%	Beta	1.21	Target Price	5.00
Payout	0.00%	Debt/Eq	0.36	Sales Q/Q	-32.36%	SMA50	15.51%	Rel Volume	0.84	Prev Close	6.79
Employees	172	LT Debt/Eq	0.04	Earnings	Nov 06 AMC	SMA200	49.71%	Avg Volume	486.79K	Price	6.94
IPO	Apr 20, 2012	Option/Short	Yes / Yes	EPS/Sales Surpr.	277.78% 1.76%	Trades		Volume	408,013	Change	2.21%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-28-21	Upgrade	Citigroup	Neutral → Buy	$11
Jun-25-20	Resumed	BofA/Merrill	Underperform	$9
Oct-08-19	Downgrade	Goldman	Neutral → Sell	$24 → $8
May-10-19	Downgrade	Citigroup	Buy → Neutral	$24
May-10-19	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$57 → $20
Jan-17-19	Initiated	Leerink Partners	Mkt Perform	$21
Jan-03-19	Downgrade	Guggenheim	Buy → Neutral
Nov-19-18	Upgrade	Goldman	Sell → Neutral
Nov-02-18	Downgrade	JP Morgan	Neutral → Underweight
Nov-02-18	Downgrade	BofA/Merrill	Buy → Underperform
Oct-01-18	Initiated	Cantor Fitzgerald	Overweight	$75
Sep-17-18	Initiated	Goldman	Sell	$42
May-11-18	Reiterated	Stifel	Buy	$95 → $87
Nov-10-17	Reiterated	RBC Capital Mkts	Sector Perform	$92 → $108
Nov-10-17	Reiterated	Citigroup	Buy	$156 → $164
Oct-02-17	Reiterated	Stifel	Buy	$110 → $130
Sep-11-17	Reiterated	Credit Suisse	Outperform	$118 → $136
Jul-10-17	Resumed	Leerink Partners	Outperform	$115
Jun-06-17	Reiterated	RBC Capital Mkts	Sector Perform	$60 → $88
May-25-17	Reiterated	RBC Capital Mkts	Sector Perform	$40 → $60

Show Previous Ratings

Feb-04-26 05:05PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-07-26 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-31-25 11:20AM	Up 91% in the Past Year, Is This Biotech Stock Red Hot or a Red Flag? (Barchart)
Dec-22-25 04:10PM	Puma Biotechnology Added to the NASDAQ Biotechnology Index (NBI) (Business Wire)
Dec-17-25 11:26AM	CRMD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Buy? (Zacks)
05:15PM	Loading…
Dec-02-25 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.57%
Nov-27-25 11:58AM	IRWD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Pick? (Zacks)
Nov-07-25 05:05PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +22.24% -21.04%
10:53AM	PBYI's Q3 Earnings & Revenues Beat Estimates, 2025 Sales View Raised (Zacks)
12:03AM	Puma Biotechnology Inc (PBYI) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst Royalty ... (GuruFocus.com)
Nov-06-25 06:00PM	Puma Biotech (PBYI) Q3 Earnings and Revenues Top Estimates (Zacks)
04:55PM	Puma Biotech: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Puma Biotechnology Reports Third Quarter 2025 Financial Results (Business Wire)
Nov-05-25 05:20PM	Acadia Pharmaceuticals (ACAD) Q3 Earnings and Revenues Top Estimates (Zacks)
Oct-23-25 04:10PM	Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results (Business Wire)
05:06AM	Loading…
Oct-09-25 05:06AM	CRISPR Therapeutics (CRSP) Surges 8.7%: Is This an Indication of Further Gains? (Zacks)
Oct-02-25 05:21PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-17-25 02:27PM	What Do Analysts Think About Puma Biotechnology (PBYI)? (Insider Monkey)
Sep-15-25 12:42PM	PBYI Surges 30% in 3 Months: How Should You Play the Stock? (Zacks)
Sep-04-25 05:25PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-02-25 04:07PM	Puma Biotechnology to Present at the H.C. Wainwright 27th Annual Global Investment Conference (Business Wire)
Sep-01-25 09:55AM	Puma Biotech (PBYI) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Aug-28-25 09:40AM	Should Value Investors Buy Puma Biotechnology (PBYI) Stock? (Zacks)
Aug-13-25 09:15AM	Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue? (Zacks) +8.83%
Aug-12-25 09:40AM	Should Value Investors Buy Puma Biotechnology (PBYI) Stock? (Zacks)
09:15AM	Puma Biotechnology, Inc. (PBYI) Soars to 52-Week High, Time to Cash Out? (Zacks)
09:11AM	Barclays Maintains a Sell Rating on Puma Biotechnology (PBYI) With a $2 PT (Insider Monkey)
Aug-08-25 05:00PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +12.16% +31.44%
10:26AM	PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues (Zacks)
Aug-07-25 05:55PM	Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
04:56PM	Loading…
04:56PM	Puma Biotech: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Puma Biotechnology Reports Second Quarter Financial Results (Business Wire)
Aug-06-25 06:05PM	Adma Biologics (ADMA) Q2 Earnings and Revenues Beat Estimates (Zacks)
Jul-24-25 04:15PM	Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2025 Financial Results (Business Wire)
Jul-15-25 08:31AM	Add These 4 Top-Ranked Liquid Stocks to Boost Portfolio Returns (Zacks)
Jul-14-25 09:40AM	Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now? (Zacks)
Jul-10-25 08:50AM	Why Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value Investors (Zacks)
Jul-08-25 10:31AM	Bayer Begins Phase I/II Study on Cell Therapy for Eye Disease (Zacks)
Jul-04-25 08:35AM	AZN's Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer (Zacks)
Jul-02-25 05:03PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:34AM	Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek (Zacks)
Jul-01-25 11:55AM	RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance (Zacks)
10:05AM	ABBV to Boost Immunology Pipeline With Capstan Buyout for $2.1B (Zacks)
Jun-30-25 10:40AM	Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why (Zacks)
Jun-27-25 10:58AM	PFE's Hympavzi Phase III Hemophilia Study With Inhibitors Meets Goal (Zacks)
09:40AM	Is Puma Biotechnology (PBYI) Stock Undervalued Right Now? (Zacks)
Jun-25-25 11:30AM	NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study (Zacks)
Jun-24-25 08:50AM	Fast-paced Momentum Stock Puma Biotech (PBYI) Is Still Trading at a Bargain (Zacks)
Jun-19-25 11:11AM	Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma (Zacks)
Jun-18-25 10:51AM	Bayer Seeks FDA Approval for MRI Contrast Agent Gadoquatrane (Zacks)
Jun-12-25 11:30AM	Why Is Exelixis (EXEL) Down 7.2% Since Last Earnings Report? (Zacks)
Jun-11-25 09:40AM	Should Value Investors Buy Puma Biotechnology (PBYI) Stock? (Zacks)
Jun-04-25 05:33PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.39%
May-28-25 08:50AM	Why Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value Investors (Zacks)
May-26-25 09:40AM	Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now? (Zacks)
May-12-25 08:50AM	Despite Fast-paced Momentum, Puma Biotech (PBYI) Is Still a Bargain Stock (Zacks)
May-09-25 09:40AM	Is Puma Biotechnology (PBYI) Stock Undervalued Right Now? (Zacks) -5.21%
08:48AM	PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates (Zacks)
03:39AM	Puma Biotechnology Inc (PBYI) Q1 2025 Earnings Call Highlights: Revenue Growth Amidst Challenges (GuruFocus.com)
May-08-25 05:55PM	Puma Biotech (PBYI) Q1 Earnings and Revenues Top Estimates (Zacks)
04:52PM	Puma Biotech: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Puma Biotechnology Reports First Quarter Financial Results (Business Wire)
May-07-25 05:20PM	Puma Biotechnology Q1 2025 Earnings Preview (Seeking Alpha)
01:25PM	Perrigo Q1 Earnings Beat Estimates, Revenues Decline Y/Y (Zacks)
11:55AM	JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook (Zacks)
08:10AM	Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-06-25 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-05-25 09:15AM	ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue? (Zacks)
May-01-25 08:05AM	Biogen Inc. (BIIB) Q1 Earnings Lag Estimates (Zacks)
Apr-30-25 12:00PM	Puma Biotech (PBYI) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
06:00AM	Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX (neratinib) for Breast Cancer Patients (GlobeNewswire)
Apr-28-25 03:03PM	Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025 (Business Wire)
Apr-24-25 04:11PM	Puma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial Results (Business Wire)
Apr-23-25 09:40AM	Should Value Investors Buy Puma Biotechnology (PBYI) Stock? (Zacks)
Apr-21-25 09:13AM	Is the Options Market Predicting a Spike in Puma Biotechnology Stock? (Zacks)
Apr-11-25 01:20PM	Puma Biotechnology: Initiating Hold Rating With Limited Near-Term Upside And Uncertain Pipeline Potential (Seeking Alpha)
Apr-02-25 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-26-25 09:00AM	Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025 (Business Wire)
Mar-20-25 12:23PM	Puma Biotechnology Stock Rises 35% in 6 Months: Here's Why (Zacks)
Mar-18-25 04:35AM	Puma Biotechnology (PBYI): One of the Best Short-Term Stocks to Buy Right Now (Insider Monkey)
Mar-05-25 06:05PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
05:30PM	Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference (Business Wire)
Mar-03-25 09:40AM	Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now? (Zacks) -6.42%
Feb-28-25 12:04PM	Q4 2024 Puma Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents) +19.73%
02:34AM	Puma Biotechnology Inc (PBYI) Q4 2024 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com)
Feb-27-25 05:29PM	Puma Biotech: Q4 Earnings Snapshot (Associated Press Finance) +7.94%
04:05PM	Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Feb-26-25 04:15PM	Puma Biotechnology to Present at TD Cowens 45th Annual Health Care Conference (Business Wire)
Feb-13-25 04:15PM	Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Feb-05-25 05:05PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-03-25 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.45% +20.34%
Jan-01-25 09:40AM	Is Puma Biotechnology (PBYI) Stock Undervalued Right Now? (Zacks)
Dec-23-24 09:01AM	Puma Biotechnologys NERLYNX Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation (Business Wire)
Dec-04-24 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-28-24 09:40AM	Should Value Investors Buy Puma Biotechnology (PBYI) Stock? (Zacks)
Nov-21-24 05:38AM	Puma commences Phase II trial of alisertib for breast cancer treatment (Clinical Trials Arena)
Nov-20-24 08:57AM	Puma Biotechnology Announces Initiation of ALISCA-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer (Business Wire)
Nov-08-24 02:27AM	Puma Biotechnology Inc (PBYI) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic ... (GuruFocus.com)
Nov-07-24 05:33PM	Puma Biotech: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Puma Biotechnology Reports Third Quarter 2024 Financial Results (Business Wire)

Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
AUERBACH ALAN H	President and CEO	Jan 07 '26	Sale	5.88	18,012	105,893	7,145,951	Jan 08 08:27 PM
AUERBACH ALAN H	President and CEO	Jan 06 '26	Sale	5.84	16,938	98,986	7,163,963	Jan 08 08:27 PM
HUNT DOUGLAS M	See Remarks	Jan 07 '26	Sale	5.88	5,014	29,477	155,907	Jan 08 08:15 PM
HUNT DOUGLAS M	See Remarks	Jan 06 '26	Sale	5.84	3,973	23,218	160,921	Jan 08 08:15 PM
NOUGUES MAXIMO F	Chief Financial Officer	Jan 07 '26	Sale	5.88	6,405	37,655	193,284	Jan 08 08:14 PM
NOUGUES MAXIMO F	Chief Financial Officer	Jan 06 '26	Sale	5.84	4,540	26,532	199,689	Jan 08 08:14 PM
AUERBACH ALAN H	Officer	Jan 07 '26	Proposed Sale	5.88	18,012	105,893		Jan 07 04:28 PM
HUNT DOUGLAS M	Officer	Jan 07 '26	Proposed Sale	5.88	5,014	29,477		Jan 07 04:25 PM
NOUGUES MAXIMO F	Officer	Jan 07 '26	Proposed Sale	5.88	6,405	37,655		Jan 07 04:24 PM
NOUGUES MAXIMO F	Officer	Jan 06 '26	Proposed Sale	5.84	4,540	26,530		Jan 06 04:53 PM
HUNT DOUGLAS M	Officer	Jan 06 '26	Proposed Sale	5.84	3,973	23,217		Jan 06 04:45 PM
AUERBACH ALAN H	Officer	Jan 06 '26	Proposed Sale	5.84	16,938	98,979		Jan 06 04:44 PM
MILLER MICHAEL PATRICK	Director	Nov 11 '25	Sale	4.86	20,000	97,228	54,000	Nov 13 04:41 PM
MILLER MICHAEL PATRICK	Director	Nov 11 '25	Proposed Sale	4.86	20,000	97,228		Nov 12 08:29 AM
Cesano Alessandra	Director	Jul 18 '25	Sale	3.37	27,000	90,909	41,850	Jul 22 07:51 PM
Cesano Alessandra	Director	Jul 18 '25	Proposed Sale	3.37	27,000	90,909		Jul 18 04:16 PM
NOUGUES MAXIMO F	Chief Financial Officer	Jul 08 '25	Sale	3.53	5,587	19,739	208,164	Jul 10 08:56 PM
NOUGUES MAXIMO F	Chief Financial Officer	Jul 09 '25	Sale	3.54	3,935	13,910	204,229	Jul 10 08:56 PM
HUNT DOUGLAS M	See Remarks	Jul 08 '25	Sale	3.53	4,374	15,453	168,337	Jul 10 08:52 PM
HUNT DOUGLAS M	See Remarks	Jul 09 '25	Sale	3.54	3,443	12,171	164,894	Jul 10 08:52 PM
AUERBACH ALAN H	President and CEO	Jul 08 '25	Sale	3.53	25,592	90,417	7,202,481	Jul 10 08:49 PM
AUERBACH ALAN H	President and CEO	Jul 09 '25	Sale	3.54	21,580	76,285	7,180,901	Jul 10 08:49 PM
NOUGUES MAXIMO F	Officer	Jul 09 '25	Proposed Sale	3.54	3,935	13,910		Jul 09 04:48 PM
AUERBACH ALAN H	Officer	Jul 09 '25	Proposed Sale	3.54	21,580	76,285		Jul 09 04:36 PM
HUNT DOUGLAS M	Officer	Jul 09 '25	Proposed Sale	3.54	3,443	12,171		Jul 09 04:27 PM
AUERBACH ALAN H	Officer	Jul 08 '25	Proposed Sale	3.53	25,592	90,424		Jul 08 04:41 PM
NOUGUES MAXIMO F	Officer	Jul 08 '25	Proposed Sale	3.53	5,587	19,741		Jul 08 04:39 PM
HUNT DOUGLAS M	Officer	Jul 08 '25	Proposed Sale	3.53	4,374	15,455		Jul 08 04:29 PM
WILSON TROY EDWARD	Director	Jun 13 '25	Sale	3.40	10,800	36,720	43,550	Jun 17 07:55 PM
Stuglik Brian M	Director	Jun 13 '25	Sale	3.39	8,100	27,459	94,958	Jun 17 07:52 PM
Senderowicz Adrian	Director	Jun 13 '25	Sale	3.40	27,000	91,800	27,000	Jun 17 07:49 PM
MOYES JAY M	Director	Jun 13 '25	Sale	3.40	22,000	74,800	53,322	Jun 17 07:46 PM
Dorval Allison	Director	Jun 13 '25	Sale	3.40	11,610	39,474	75,390	Jun 17 07:43 PM
Cesano Alessandra	Director	Jun 13 '25	Sale	3.40	12,150	41,310	68,850	Jun 17 07:41 PM
WILSON TROY EDWARD	Director	Jun 13 '25	Proposed Sale	3.40	10,800	36,678		Jun 13 04:15 PM
Senderowicz Adrian	Director	Jun 13 '25	Proposed Sale	3.40	27,000	91,767		Jun 13 04:11 PM
Dorval Allison	Director	Jun 13 '25	Proposed Sale	3.40	11,610	39,437		Jun 13 04:10 PM
Cesano Alessandra	Director	Jun 13 '25	Proposed Sale	3.40	12,150	41,285		Jun 13 04:09 PM
Stuglik Brian M	Director	Jun 13 '25	Proposed Sale	3.39	8,100	27,497		Jun 13 04:07 PM
MOYES JAY M	Director	Jun 13 '25	Proposed Sale	3.40	22,000	74,756		Jun 13 04:04 PM
Ludwig Jeffrey Jerome	Former Officer	May 21 '25	Proposed Sale	3.42	55,882	191,310		May 21 03:00 PM

Open in Screener

KURA

Kura Oncology Inc

Feb 06 • 04:00PM ET

7.83

+0.43 5.81 %

Healthcare • Biotechnology • USA • NASD

KURA Kura Oncology Inc daily Stock Chart

Peers: AGIO BLUE FATE ADAP EXEL IOVA KPTI KYNB

| Held by: VTI XBI IWM VXF AVUV IWN IBB VTWO SCHA VHT

Index	RUT	P/E	-	EPS (ttm)	-2.48	Insider Own	3.25%	Shs Outstand	87.02M	Perf Week	-3.57%
Market Cap	681.35M	Forward P/E	-	EPS next Y	-3.25	Insider Trans	-3.17%	Shs Float	84.19M	Perf Month	-21.46%
Enterprise Value	151.16M	PEG	-	EPS next Q	-0.66	Inst Own	97.72%	Short Float	14.62%	Perf Quarter	-21.23%
Income	-216.88M	P/S	6.55	EPS this Y	-43.26%	Inst Trans	1.05%	Short Ratio	7.48	Perf Half Y	31.38%
Sales	104.03M	P/B	2.81	EPS next Y	-12.21%	ROA	-38.45%	Short Interest	12.31M	Perf YTD	-24.64%
Book/sh	2.79	P/C	1.24	EPS next 5Y	-6.73%	ROE	-65.10%	52W High	12.49 -37.31%	Perf Year	-13.48%
Cash/sh	6.32	P/FCF	8.20	EPS past 3/5Y	-0.89% -6.05%	ROIC	-84.64%	52W Low	5.41 44.73%	Perf 3Y	-43.63%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	99.20%	Volatility	5.25% 4.84%	Perf 5Y	-75.06%
Dividend TTM	-	EV/Sales	1.45	EPS Y/Y TTM	-5.18%	Oper. Margin	-230.53%	ATR (14)	0.45	Perf 10Y	63.12%
Dividend Ex-Date	-	Quick Ratio	5.12	Sales Y/Y TTM	-	Profit Margin	-208.48%	RSI (14)	36.49	Recom	1.33
Dividend Gr. 3/5Y	- -	Current Ratio	5.12	EPS Q/Q	-35.14%	SMA20	-8.30%	Beta	0.26	Target Price	32.45
Payout	-	Debt/Eq	0.08	Sales Q/Q	-	SMA50	-20.67%	Rel Volume	0.94	Prev Close	7.40
Employees	192	LT Debt/Eq	0.06	Earnings	Nov 04 BMO	SMA200	-4.37%	Avg Volume	1.65M	Price	7.83
IPO	Sep 16, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-16.44% 9.57%	Trades		Volume	1,539,147	Change	5.81%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-04-25	Initiated	Guggenheim	Neutral
Feb-06-25	Downgrade	BTIG Research	Buy → Neutral
Oct-24-24	Initiated	UBS	Buy	$27
Oct-14-24	Downgrade	Stifel	Buy → Hold	$26 → $19
Dec-22-23	Initiated	Mizuho	Buy	$26
Aug-11-23	Initiated	BofA Securities	Buy	$31
Jul-27-23	Initiated	Scotiabank	Sector Perform	$10.50
May-17-23	Initiated	BTIG Research	Buy	$31
Jan-31-23	Initiated	Stifel	Buy	$25
Jul-12-22	Initiated	Cantor Fitzgerald	Overweight	$30
Feb-15-22	Initiated	Jefferies	Buy	$35
May-05-21	Resumed	Credit Suisse	Outperform	$42
Apr-26-21	Resumed	Credit Suisse	Outperform	$42
Dec-07-20	Reiterated	H.C. Wainwright	Buy	$40 → $45
Dec-03-20	Initiated	Stifel	Buy	$45
Nov-05-20	Downgrade	Piper Sandler	Overweight → Neutral
Jul-07-20	Initiated	Credit Suisse	Outperform	$27
May-05-20	Initiated	Barclays	Overweight	$24
Jul-18-19	Initiated	Deutsche Bank	Buy	$28
Nov-09-18	Initiated	Piper Jaffray	Overweight

Show Previous Ratings

Feb-06-26 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.81%
Feb-02-26 09:36AM	Analyst Flags Kura Oncology, Inc. (KURA) for 2026 Milestones and Pipeline Expansion (Insider Monkey)
Jan-21-26 04:51AM	New Strong Sell Stocks for January 21st (Zacks)
Jan-14-26 09:16AM	Kura Oncology price target lowered to $20 from $25 at Leerink (TipRanks)
Jan-11-26 05:00PM	Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones (GlobeNewswire)
07:30AM	Loading…
Jan-05-26 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.69%
Dec-23-25 12:52AM	Jim Cramer Calls Kura Speculative But Says "It's One of the Stronger Ones I've Seen in a Very Long Time" (Insider Monkey)
Dec-21-25 10:26AM	Jim Cramer Discusses Kura Oncology as a Speculative Bet (Insider Monkey)
Dec-18-25 07:58PM	Lightning Round: Don't get involved in any 'year of magical investing' stock: Jim Cramer (CNBC TV)
Dec-15-25 11:10PM	Kura Oncology (KURA) Gains Momentum as Barclays Sees Significant Potential in Ziftomenib Approval (Insider Monkey)
Dec-08-25 10:30AM	Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML (GlobeNewswire)
Dec-04-25 12:20PM	Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points (PR Newswire)
Dec-03-25 08:32AM	Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia (GlobeNewswire) +7.55%
Dec-02-25 08:02AM	First U.S. Commercial Sale of KOMZIFTI Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin (GlobeNewswire)
Nov-25-25 05:16PM	KOMZIFTI (ziftomenib) Added to National Comprehensive Cancer Network (NCCN) Guidelines for Acute Myeloid Leukemia (AML) (GlobeNewswire)
07:15AM	Loading…
Nov-14-25 07:15AM	Kura and Kyowa Kirin secure FDA go-ahead for targeted leukaemia therapy (Pharmaceutical Technology)
06:06AM	Lundbeck sparks bidding war with Alkermes; Pfizer closes Metsera deal (BioPharma Dive)
Nov-13-25 10:51AM	Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia (GlobeNewswire)
Nov-12-25 04:05PM	Kura Oncology to Participate in Upcoming Investor Conference (GlobeNewswire)
Nov-07-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-04-25 04:03PM	Kura Oncology Inc (KURA) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Rising Expenses (GuruFocus.com)
07:45AM	Kura Oncology (KURA) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
06:50AM	Kura Oncology: Q3 Earnings Snapshot (Associated Press Finance)
06:31AM	Kura Oncology Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-03-25 04:02PM	Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin (GlobeNewswire)
09:14AM	Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia at 2025 ASH Annual Meeting (GlobeNewswire)
07:50AM	What To Expect From Kura Oncology Inc (KURA) Q3 2025 Earnings (GuruFocus.com)
Oct-28-25 04:01PM	Kura Oncology to Report Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-24-25 07:02AM	Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin (GlobeNewswire) +6.59%
Oct-18-25 03:23AM	Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress (GlobeNewswire)
07:30AM	Loading…
Oct-03-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-01-25 07:01AM	Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) (GlobeNewswire)
Sep-29-25 04:01PM	Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML) (GlobeNewswire)
Sep-25-25 05:18PM	Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology (GlobeNewswire) +8.25%
Sep-24-25 07:30AM	Kura Oncology to Participate in Upcoming Investor Conference (GlobeNewswire)
Sep-16-25 04:01PM	Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types (GlobeNewswire)
Sep-08-25 12:30AM	LifeSci Capital Maintains Buy Rating on Kura Oncology (KURA) (Insider Monkey)
Sep-05-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-03-25 08:02AM	Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program (GlobeNewswire) +6.04%
Aug-28-25 07:30AM	Kura Oncology to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Aug-07-25 06:15PM	Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -7.05%
05:16PM	Kura Oncology: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Kura Oncology Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-06-25 07:00AM	OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee (GlobeNewswire) -5.19%
Aug-04-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-31-25 07:30AM	Kura Oncology to Report Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-03-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-12-25 08:48AM	Is the Options Market Predicting a Spike in Kura Oncology Stock? (Zacks)
07:30AM	Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress (GlobeNewswire)
Jun-10-25 08:08PM	Lightning Round: 'Wait and see situation' with Papa John's, says Jim Cramer (CNBC TV)
Jun-06-25 11:52AM	KURA Stock Rises More Than 15% This Past Week: Here's Why (Zacks)
07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-02-25 06:00PM	Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting (GlobeNewswire) +10.72%
Jun-01-25 07:00PM	Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML (GlobeNewswire)
May-22-25 05:30PM	Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting (GlobeNewswire) -9.62%
May-20-25 07:30AM	Kura Oncology to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
May-14-25 10:00AM	Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress (GlobeNewswire)
May-06-25 07:30AM	Kura Oncology to Participate in Bank of America Securities Healthcare Conference (GlobeNewswire) -13.84%
May-02-25 10:51AM	Q1 2025 Kura Oncology Inc Earnings Call (Thomson Reuters StreetEvents)
07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
03:17AM	Kura Oncology Inc (KURA) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Rising Costs (GuruFocus.com)
May-01-25 08:48PM	Kura Oncology, Inc. (KURA) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:25PM	Kura Oncology (KURA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:26PM	Kura Oncology: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Kura Oncology Reports First Quarter 2025 Financial Results (GlobeNewswire)
Apr-29-25 05:27AM	Kura doses first subjects in trial of ziftomenib for advanced GIST (Clinical Trials Arena)
Apr-28-25 07:30AM	Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST (GlobeNewswire)
Apr-24-25 07:30AM	Kura Oncology to Report First Quarter 2025 Financial Results (GlobeNewswire)
Apr-08-25 07:30AM	Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA (GlobeNewswire)
Apr-07-25 09:08AM	Syndax Pharmaceuticals: Down But Not Out (Seeking Alpha)
Apr-04-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-01-25 07:30AM	Kura Oncology to Participate in Stifel Targeted Oncology Forum (GlobeNewswire)
Mar-26-25 07:30AM	Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting (GlobeNewswire)
Mar-07-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-27-25 11:19AM	Q4 2024 Kura Oncology Inc Earnings Call (Thomson Reuters StreetEvents)
02:24AM	Kura Oncology Inc (KURA) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Growth (GuruFocus.com)
Feb-26-25 05:35PM	Kura Oncology (KURA) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:42PM	Kura Oncology: Q4 Earnings Snapshot (Associated Press Finance)
04:03PM	Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-25-25 07:30AM	Kura Oncology to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Feb-19-25 07:30AM	Kura Oncology to Report Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-07-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-05-25 04:01PM	Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs (GlobeNewswire)
Jan-06-25 04:30PM	Kura Oncology Announces Senior Executive Promotions (GlobeNewswire)
Dec-09-24 07:00AM	Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting (GlobeNewswire)
Dec-04-24 01:25PM	Why Is Kura Oncology, Inc. (KURA) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? (Insider Monkey)
Dec-02-24 07:30AM	Kura Oncology to Host Virtual Investor Event on December 9, 2024 (GlobeNewswire)
Nov-25-24 07:30AM	Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit (GlobeNewswire)
Nov-23-24 10:42AM	Kura Oncology, Inc. (KURA): Among the Most Promising Cancer Stocks According to Hedge Funds (Insider Monkey)
Nov-22-24 05:30AM	Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial (BioPharma Dive) +7.36%
Nov-21-24 04:15PM	Kura Crashes 37% After $1.53 Billion Deal Slams The Door On A Takeover (Investor's Business Daily) -36.77%
09:05AM	Kura Oncology Slams The Door On Its Takeover Narrative, And Shares Collapse 26% (Investor's Business Daily)
06:37AM	Kura Oncology partners Kyowa Kirin to advance AML treatment (Pharmaceutical Technology)
Nov-20-24 05:00PM	Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias (PR Newswire)
Nov-08-24 04:01PM	Kura Oncology Inc (KURA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising Expenses (GuruFocus.com)
Nov-07-24 05:15PM	Kura Oncology: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Kura Oncology Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-05-24 09:09AM	Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting (GlobeNewswire)
Oct-31-24 07:30AM	Kura Oncology to Report Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-29-24 08:00AM	Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors (Business Wire)

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Powl Brian T.	Chief Commercial Officer	Jan 27 '26	Sale	8.46	6,414	54,266	183,275	Jan 27 09:35 PM
FORD KATHLEEN	Chief Operating Officer	Jan 27 '26	Sale	8.46	1,813	15,339	153,560	Jan 27 09:35 PM
Leoni Mollie	Chief Medical Officer	Jan 27 '26	Sale	8.46	8,180	69,209	267,274	Jan 27 09:35 PM
DOYLE THOMAS JAMES	SVP, Finance & Accounting	Jan 27 '26	Sale	8.46	7,142	60,426	145,167	Jan 27 09:35 PM
Burrows Francis	Chief Scientific Officer	Jan 27 '26	Sale	8.46	1,311	11,092	32,424	Jan 27 09:35 PM
Bair Teresa Brophy	Chief Legal Officer	Jan 27 '26	Sale	8.46	11,208	94,828	226,931	Jan 27 09:35 PM
BAIR TERESA BROPHY	Officer	Jan 27 '26	Proposed Sale	8.47	11,208	94,932		Jan 27 09:30 PM
POWL BRIAN T	Officer	Jan 27 '26	Proposed Sale	8.47	6,414	54,327		Jan 27 09:30 PM
FORD KATHLEEN	Officer	Jan 27 '26	Proposed Sale	8.47	1,813	15,356		Jan 27 09:30 PM
LEONI MOLLIE	Officer	Jan 27 '26	Proposed Sale	8.47	8,180	69,285		Jan 27 09:30 PM
BURROWS FRANCIS	Officer	Jan 27 '26	Proposed Sale	8.47	1,311	11,104		Jan 27 09:30 PM
DOYLE THOMAS JAMES	Officer	Jan 27 '26	Proposed Sale	8.47	7,142	60,493		Jan 27 09:30 PM
Burrows Francis	Chief Scientific Officer	Dec 18 '25	Option Exercise	4.80	35,000	168,000	57,461	Dec 19 04:30 PM
Burrows Francis	Chief Scientific Officer	Dec 18 '25	Sale	9.78	23,726	231,931	33,735	Dec 19 04:30 PM
FRANCIS J BURROWS	Officer	Dec 18 '25	Proposed Sale	9.78	23,726	231,934		Dec 18 04:07 PM
Hasnain Faheem	Director	Dec 09 '25	Option Exercise	3.12	10,000	31,200	33,983	Dec 10 04:05 PM
Hasnain Faheem	Director	Dec 09 '25	Sale	10.98	10,000	109,764	23,983	Dec 10 04:05 PM
FAHEEM HASNAIN	Director	Dec 09 '25	Proposed Sale	11.64	10,000	116,400		Dec 09 04:23 PM
Bair Teresa Brophy	Chief Legal Officer	Nov 14 '25	Sale	11.18	8,804	98,401	188,139	Nov 14 08:00 PM
Powl Brian T.	Chief Commercial Officer	Nov 14 '25	Sale	11.18	8,887	99,329	139,689	Nov 14 08:00 PM
Leoni Mollie	Chief Medical Officer	Nov 14 '25	Sale	11.18	15,485	173,074	225,454	Nov 14 08:00 PM
DOYLE THOMAS JAMES	SVP, Finance & Accounting	Nov 14 '25	Sale	11.18	4,539	50,732	130,257	Nov 14 08:00 PM
FORD KATHLEEN	Officer	Nov 14 '25	Proposed Sale	10.68	6,902	73,713		Nov 14 08:00 PM
DOYLE THOMAS JAMES	Officer	Nov 14 '25	Proposed Sale	10.68	4,539	48,477		Nov 14 08:00 PM
FORD KATHLEEN	Chief Operating Officer	Nov 14 '25	Sale	11.18	6,902	77,143	105,373	Nov 14 08:00 PM
LEONI MOLLIE	Officer	Nov 14 '25	Proposed Sale	10.68	15,485	165,380		Nov 14 08:00 PM
POWL BRIAN T	Officer	Nov 14 '25	Proposed Sale	10.68	8,887	94,913		Nov 14 08:00 PM
BAIR TERESA BROPHY	Officer	Nov 14 '25	Proposed Sale	10.68	8,804	94,027		Nov 14 08:00 PM
WILSON TROY EDWARD	Officer	Sep 29 '25	Proposed Sale	9.05	36,615	331,366		Sep 29 07:50 PM
LEONI MOLLIE	Officer	Sep 29 '25	Proposed Sale	9.05	12,314	111,442		Sep 29 07:50 PM
POWL BRIAN T	Officer	Sep 29 '25	Proposed Sale	9.05	8,891	80,464		Sep 29 07:50 PM
BAIR TERESA BROPHY	Officer	Sep 29 '25	Proposed Sale	9.05	8,805	79,685		Sep 29 07:50 PM
DOYLE THOMAS JAMES	Officer	Sep 29 '25	Proposed Sale	9.05	4,541	41,096		Sep 29 07:50 PM
FORD KATHLEEN	Officer	Sep 29 '25	Proposed Sale	9.05	6,892	62,373		Sep 29 07:50 PM
Powl Brian T.	Chief Commercial Officer	Sep 29 '25	Sale	8.94	8,891	79,505	99,676	Sep 29 07:30 PM
Bair Teresa Brophy	Chief Legal Officer	Sep 29 '25	Sale	8.94	8,805	78,736	148,043	Sep 29 07:30 PM
FORD KATHLEEN	Chief Operating Officer	Sep 29 '25	Sale	8.94	6,892	61,630	63,375	Sep 29 07:30 PM
Leoni Mollie	Chief Medical Officer	Sep 29 '25	Sale	8.94	12,314	110,114	158,439	Sep 29 07:30 PM
WILSON TROY EDWARD	President and CEO	Sep 29 '25	Sale	8.94	36,615	327,419	246,853	Sep 29 07:30 PM
DOYLE THOMAS JAMES	SVP, Finance & Accounting	Sep 29 '25	Sale	8.94	4,541	40,607	109,829	Sep 29 07:30 PM
WILSON TROY EDWARD	President & CEO	Sep 08 '25	Buy	8.20	50,000	410,145	100,968	Sep 09 04:28 PM
WILSON TROY EDWARD	President and CEO	Aug 12 '25	Buy	5.85	36,506	213,578	37,474	Aug 14 04:05 PM
WILSON TROY EDWARD	President and CEO	Aug 13 '25	Buy	6.64	13,494	89,623	50,968	Aug 14 04:05 PM
Bair Teresa Brophy	Chief Legal Officer	May 19 '25	Sale	5.96	1,559	9,292	107,948	May 19 06:30 PM
FORD KATHLEEN	Chief Operating Officer	May 19 '25	Sale	6.28	1,558	9,777	21,367	May 19 06:30 PM
FORD KATHLEEN	Officer	May 19 '25	Proposed Sale	5.96	1,558	9,286		May 19 04:06 PM
Hasnain Faheem	Director	Mar 21 '25	Option Exercise	6.32	22,682	143,350	46,665	Mar 24 04:33 PM
Hasnain Faheem	Director	Mar 21 '25	Sale	8.00	22,682	181,456	23,983	Mar 24 04:33 PM
FAHEEM HASNAIN	Director	Mar 21 '25	Proposed Sale	7.85	30,000	235,500		Mar 21 04:21 PM

PBYI

Puma Biotechnology Inc

KURA

Kura Oncology Inc

Upgrade your FINVIZ experience